André Bourgouin

André Bourgouin
André Bourgouin is an experienced patent professional who started his career at the patent department of the then French company ROUSSEL UCLAF (now part of the Sanofi group) where he was early on involved in complex procedures like multi-party interferences in the US and appeals in Japan. He later joined Pasteur Mérieux (now Sanofi Pasteur) just after the acquisition of Connaught Laboratories. When at Pasteur Mérieux, André participated in the first patent disputes concerning recombinant vaccines. He was later on appointed Vice-President Intellectual property at IPSEN. In this capacity he developed a robust in-house IP function and successfully secured protection …
André Bourgouin is an experienced patent professional who started his career at the patent department of the then French company ROUSSEL UCLAF (now part of the Sanofi group) where he was early on involved in complex procedures like multi-party interferences in the US and appeals in Japan. He later joined Pasteur Mérieux (now Sanofi Pasteur) just after the acquisition of Connaught Laboratories. When at Pasteur Mérieux, André participated in the first patent disputes concerning recombinant vaccines. He was later on appointed Vice-President Intellectual property at IPSEN. In this capacity he developed a robust in-house IP function and successfully secured protection and freedom to operate for IPSEN leading products in intricate and conflictual patent situations.

For the last 10 years or so, André has been practicing patent law in the private practice as a partner of the Paris-based Grosset-Fournier & Demachy patent firm where he advises start-ups and medium-sized companies operating in the pharmaceutical field.

André has read chemistry, civil and patent law. He holds a Doctorate degree in organic chemistry, a Bachelor’s degree in Civil law and a Master’s degree in Patent law. He is a registered French and European Patent and Trademark attorney.
See more

Articles: André Bourgouin

China Strives for First-In-Class Drug Innovation with New Patent Law

China / In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the country’s domestic biopharma innovation landscape and the ability of breakthrough drugs from MNCs to make it onto the Chinese market.    July 2021 was a…

See more